In Vivo EGFR Molecular Classification and Treatment Response

Study Overview
=================
Brief Summary
-----------------
The investigators developed 18F-MPG as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status. And use 18F-MPG to monitor EGFR-TKIs and chemotherapy treatment efficiency.

Detailed Description
-----------------
The goal of investigators were to evaluate the use of 18F-MPG as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-MPG in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers. And the investigators want to evaluated the use of 18F-MPG in adult NSCLC patients with EGFR mutational status received non-treatment, EGFR-TKIs and chemotherapy.

Official Title
-----------------
An EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients Identification Strategy and Treatment Response Using Molecular Imaging

Conditions
-----------------
Molecular Imaging

Intervention / Treatment
-----------------
* Other: 18F-MPG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced NSCLC 18 years or older A life expectancy of at least 12 weeks Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT) Written informed consent Exclusion Criteria: Claustrophobia Pregnancy Metal implants in the thorax

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 18F-MPG:EGFR+<br>Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study. | Other: 18F-MPG<br>* N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)<br>|
| Experimental: 18F-MPG:post-TKI EGFR+<br>Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study. | Other: 18F-MPG<br>* N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)<br>|
| Experimental: 18F-MPG:post-chemo EGFR+<br>Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study. | Other: 18F-MPG<br>* N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)<br>|
| Experimental: 18F-MPG:EGFR wild type<br>Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study. | Other: 18F-MPG<br>* N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)<br>|
| Experimental: 18F-MPG:post-chemo EGFR wild type<br>Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study. | Other: 18F-MPG<br>* N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)<br>|
| Experimental: 18F-MPG:unknown EGFR mutational status<br>Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group | Other: 18F-MPG<br>* N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tumor SUVmax value of 18F-MPG PET/CT Imaging | To quantify the accumulation, a volume of interest using a 3-D sphere, was placed over the primary lung tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal lung tissue as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare). The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest. | at time of imaging |